Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
JAMA Oncology Author Interviews
Release Date: 05/19/2022
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
JAMA Oncology Author Interviews
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.
info_outline
Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
JAMA Oncology Author Interviews
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.
info_outline
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
JAMA Oncology Author Interviews
Interview with Eileen M. O’Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD.
info_outline
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
JAMA Oncology Author Interviews
Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD.
info_outline
Neoadjuvant Exercise Therapy in Prostate Cancer
JAMA Oncology Author Interviews
Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD.
info_outline
Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals
JAMA Oncology Author Interviews
Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD.
info_outline
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
JAMA Oncology Author Interviews
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.
info_outline
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
JAMA Oncology Author Interviews
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD.
info_outline
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
JAMA Oncology Author Interviews
Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD.
info_outline
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
JAMA Oncology Author Interviews
Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD.
info_outlineInterview with Lars Björnebo, MSc, and Anna Lantz, MD, PhD, authors of Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. Hosted by Jack West, MD.